Practical considerations and questions in the treatment of chronic lymphocytic leukemia

[Guest guest]

Blank[Practical considerations and questions in the treatment of chronic

lymphocytic leukemia.]

B Telek, L Rejt?, P Batar, G Remenyi, R Szasz, A Kiss, and M Udvardy

Orv Hetil, June 1, 2011; 152(24): 958-963.

Debreceni Egyetem, Orvos- ?s Eg?szs?gtudomanyi Centrum, Altalanos Orvostudom?nyi

Kar II. Belgy?gy?szati Klinika, Hematological Tanszek Debrecen Pf. 20 4012.

Understanding the pathogenesis and refine the treatment of chronic lymphocytic

leukemia have been tremendously improved in the past decade. Treatment outcome

and estimated prognosis have become more accurate due to the advanced molecular

biological techniques and the classical prognostic markers. Incorporation of

fludarabine and rituximab into the standard protocols fundamentally improved

treatment outcome in chronic lymphocytic leukemia. Chemoimmunotherapy has

improved not only the remission rates but had a significant impact on overall

survival, as well. Eliminating residual leukemia and achieving complete

hematological remissions at such high rates establish potential background for

cure. Still, a great deal of dispute has been emerged regarding everyday

clinical practice. Authors present their institutional experiences and review

the literature. Orv. Hetil., 2011, 152, 958-963.

PMID: 21609922